IP Library Granted Patent US 7,419,944
Granted Patent B2
US 7,419,944 · App. 09/997,099 · Granted Sep 2, 2008

Aqueous disinfecting systems

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,419,944
App. No.
09/997,099
Granted
Sep 2, 2008
Kind
B2
Abstract

Compositions effective as disinfecting solutions for ophthalmic devices such as contact lenses are provided. The compositions include a microbicide, preferably polyhexamethylene biguanide or alexidine, and a water soluble salt of a bis-aminopolyol, preferably 1,3-bis(tris[hydroxymethyl]methylamino)propane, as a buffering agent.

Claims (9)

1. An aqueous solution for disinfecting a contact lens, comprising: from 0.1 to 10 ppm of a microbicide selected from the group consisting of polyhexamethylene biguanide and alexidine; and 0.001 to 0.2 mol/L of 1,3-bis(tris[hydroxylmethyl]methylamino)propane or a salt thereof as buffering agent, wherein the aqueous solution buffered by 1,3-bis(tris[hydroxylmethyl]methylamino)propane is characterized by having a disinfecting efficacy that is at least 1.0 log of reduction greater than a disinfecting solution containing the same amount of the microbiocide but buffered with a phosphate buffer, wherein said solution has a pH of 6.8 to 7.5.

2. The aqueous solution of claim 1 further comprising a chelating agent.

3. The aqueous solution of claim 2 wherein said chelating agent is selected from the group consisting of ethylene diamine tetraacetic acid, diethylene triamine pentaacetic acid, salts thereof, and mixtures thereof.

4. The aqueous solution of claim 1 further comprising a surfactant.

5. The aqueous solution of claim 4 wherein said surfactant is selected from the group consisting of poloxomers, poloxamines, octoxynol, hydroxylated castor oil, and tyloxapol.

6. The aqueous solution of claim 1 further comprising a tonicity agent.

7. The aqueous solution of claim 6 wherein said tonicity agent is sodium chloride.

8. The aqueous solution of claim 1 further comprising a viscosity modifying agent.

9. The aqueous solution of claim 8 wherein said viscosity modifying agent is selected from the group consisting of lecithin, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and methylcellulose, polyvinyl alcohol, and polyvinyl pyrolidone.

Assignments (2)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2008
From: MOWREY-MCKEE, MARY; AJELLO, MARC
To: NOVARTIS AG
Reel/Frame 021017/0867 →
Continuity (2)
Provisional Application 6025375700 · Nov 29, 2000
Related Publication 20020122831A1 · Sep 5, 2002